This study revealed that EMPA treatment can alleviate TAC-induced cardiac hypertrophy by directly inhibiting the FZD4/Wnt/β-catenin/TCF7L2 pathway in cardiomyocytes (Figure 6G). This evidence concerns the gene TCF7L2 and cardiac hypertrophy.